Literature DB >> 17053983

Twitch potentiation influences the time course of twitch depression in muscle relaxant studies: a pharmacokinetic-pharmacodynamic explanation.

Douglas J Eleveld1, Johannes H Proost, J Mark K H Wierda.   

Abstract

The time course of twitch depression following neuromuscular blocking agent (NMBA) administration is influenced by the duration of control neuromuscular monitoring (twitch stabilization). The physiological mechanism for this interaction is not known. During twitch stabilization twitch response often increases to a plateau, this is known as twitch potentiation or the staircase phenomenon. Since twitch potentiation contributes to the observed twitch response it may also influence the time course of twitch depression following NMBA administration. Our objective was to estimate the degree that twitch potentiation influences the time course of twitch depression following NMBA administration under conditions typical for muscle relaxation studies. We used previousy described pharmacokinetic-pharmacodynamic (PK-PD) and twitch potentiation models to simulate twitch data. Simulations consisted of twitch stabilization followed by a NMBA bolus dose and subsequent onset and recovery from muscle relaxation. Twitch data were analyzed for onset and recovery characteristics and the results compared to clinical muscle relaxation studies in existing literature. We found that twitch potentiation likely plays a minor role in shortened onset time and increased duration of twitch depression observed with long periods of twitch stabilization.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17053983     DOI: 10.1007/s10928-006-9034-0

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  20 in total

1.  The effect of previous stimulation on the active state of muscle.

Authors:  J M RITCHIE; D R WILKIE
Journal:  J Physiol       Date:  1955-11-28       Impact factor: 5.182

2.  Improving pharmacokinetic-pharmacodynamic models of muscle relaxants using potentiation modelling.

Authors:  Douglas J Eleveld; Johannes H Proost; Ann De Haes; J Mark K H Wierda
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-02       Impact factor: 2.745

3.  Onset and recovery of atracurium and suxamethonium-induced neuromuscular blockade with simultaneous train-of-four and single twitch stimulation.

Authors:  M J Curran; F Donati; D R Bevan
Journal:  Br J Anaesth       Date:  1987-08       Impact factor: 9.166

4.  A two-step iterative algorithm for estimation in nonlinear mixed-effect models with an evaluation in population pharmacokinetics.

Authors:  F Mentré; R Gomeni
Journal:  J Biopharm Stat       Date:  1995-07       Impact factor: 1.051

5.  The influence of the duration of control stimulation on the onset and recovery of neuromuscular block.

Authors:  E P McCoy; R K Mirakhur; F M Connolly; P B Loan
Journal:  Anesth Analg       Date:  1995-02       Impact factor: 5.108

6.  The effect of low frequency stimulation on myosin light chain phosphorylation in skeletal muscle.

Authors:  G A Klug; B R Botterman; J T Stull
Journal:  J Biol Chem       Date:  1982-05-10       Impact factor: 5.157

7.  Improving the design of muscle relaxant studies. Stabilization period and tetanic recruitment.

Authors:  G C Lee; S Iyengar; J Szenohradszky; J E Caldwell; P M Wright; R Brown; M Lau; A Luks; D M Fisher
Journal:  Anesthesiology       Date:  1997-01       Impact factor: 7.892

8.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine.

Authors:  L B Sheiner; D R Stanski; S Vozeh; R D Miller; J Ham
Journal:  Clin Pharmacol Ther       Date:  1979-03       Impact factor: 6.875

Review 9.  Myosin light chain phosphorylation in vertebrate striated muscle: regulation and function.

Authors:  H L Sweeney; B F Bowman; J T Stull
Journal:  Am J Physiol       Date:  1993-05

10.  The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods.

Authors:  L B Sheiner
Journal:  Drug Metab Rev       Date:  1984       Impact factor: 4.518

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.